Clinical Trial

Brain Oligometastasis in NSCLC

Study acronym: OligoLung
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 5, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute
Trial Details
NCT Number NCT07389642
Lead Sponsor University Hospital, Bordeaux
Conditions Brain Oligometastatic, Non-small Cell Lung Cancer
Enrollment 46 participants
Start Date 2025-01-01
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-05